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Solifenacin is an M3- muscarinic receptor antagonist that is effective in the treatment of 
overactive bladder (OAB), reducing episodes of urgency and incontinence and decreasing 
micturition frequency (Luo et al., 2012). It can be used alone or in combination with other 
agents. For example, fixed dose combinations with tamsulosin appear to be well tolerated 
and effective in men with lower urinary tract symptoms (Drake et al., 2015). 
The CredibleMeds® database (https://www.crediblemeds.org/) provides information on 
drugs linked to QT interval prolongation and Torsades de Pointes (TdP) arrhythmia. It 
categorises drugs associated with these ECG alterations according to strength of evidence of 
causality (for a review see Schwartz and Woosley, 2016). In September 2016, solifenacin 
was recategorised on CredibleMeds® as having a ‘possible risk of TdP’, which means that 
the drug is associated with QT interval prolongation but lacks evidence for TdP when taken 
as recommended. The recent Symphony study in patients ≥18 years found small increases 
in mean QTcF interval (Fridericia’s correction) following 12 weeks of 2.5, 5 or 10 mg day-1 
solifenacin (Abrams et al., 2015). In the MILAI study, 2.4% of patients at end of treatment 
with 2.5 or 5 mg day-1 had QTcF intervals exceeding 450 ms, whilst 1.4% had QTcF 
lengthening between 30 and 60 ms (Yamaguchi et al., 2015). In December 2016 we 
reviewed the case report evidence for QTc prolongation with solifenacin (PubMed search: 
“solifenacin AND (QTc OR torsad*)” and found 3 reports of TdP with normal solifenacin use, 
the features of which are considered below. 
The first case involved an 81-year-old-woman (Asajima et al., 2008). Her past medical 
history included hypertension, receipt of a pacemaker for sick sinus syndrome and 
amlodipine, and she had recently received cefazolin and subsequently teicoplanin for 
methicillin-resistant Staph aureus. Neither drug is independently associated with QT 
prolongation or TdP; her QT interval was normal prior to the prescription of solifenacin (QT 
400 ms/QTc 360 ms). However, after two weeks of taking 5 mg day-1 solifenacin, she 
developed an isolated syncopal episode from which she regained full consciousness 
spontaneously.  Electrocardiogram (ECG) measurement showed marked QT prolongation 
(QT 600 ms/ QTc 581 ms). Nine days later this progressed to recurrent episodes of syncope 
and concomitant TdP, which required resuscitation. Risk factors which predispose an 
individual to aLQTS include female sex and bradycardia; however, her pacemaker rate was 
increased from 60 beats min-1 to 90 beats min-1 to abbreviate the QT interval (QT 500 
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ms/QTc 408 ms) following solifenacin withdrawal. Electrocardiographic abnormalities 
resolved within days of solifenacin discontinuation. Aside from age, there were no other 
obvious risk factors including the cumulative effect from co-administration of other QT 
prolonging agents, impaired liver function, hypokalemia or hypomagnesemia. Interestingly, 
intravenous magnesium sulphate which is considered a first-line treatment for drug-induced 
TdP was not effective.  
The second case in 2012 concerned an 81-year old man who also presented with a syncopal 
episode and QT prolongation (QT 680 ms/QTc 660 ms) (Yoshida et al., 2014). It was 
recognised that the patient was suffering from hypoglycaemia, possibly caused by the class 
1a antiarrhythmic cibenzoline (given to protect against atrial fibrillation), which was 
discontinued on admission. However, after two days of hospitalisation he developed 
recurrent episodes of syncope and TdP requiring resuscitation. Infusion of magnesium 
sulphate was followed by temporary transcutaneous pacing which alleviated episodes of 
TdP by shortening QT interval. Following resuscitation, on day 3 solifenacin (10 mg day-1) 
was discontinued and 5 days after the initial episode, QTc interval had reduced to 458 ms. 
There is conflicting evidence as to whether or not cibenzoline itself prolongs QTc (Kushner 
et al., 1984, Rothbart and Saksena, 1986, Miyamoto et al., 2000). Three other risk factors 
additional to age in this case can be highlighted, however; on admission the patient was 
hypoglycaemic (1.1 mmol/L), borderline bradycardic (57 bpm), and during the 5 day period 
he was also borderline hypokalaemic (3.1- 3.6 mEq/ml).  
In 2015, an 84-year-old male presented to hospital with episodes of syncope having taken 
solifenacin 10 mg day-1 for 15 days (Ozmen et al., 2015). During evaluation the patient lost 
consciousness and a sustained ventricular tachycardia was measured. Following 
resuscitation a prolonged QTC interval of 548 ms was observed. Again magnesium sulphate 
was ineffective at preventing recurrence of the dangerous cardiac arrhythmia and a 
temporary pacemaker was implanted. Solifenacin was subsequently discontinued and 3 
days later the QT interval was 420 ms and TdP did not recur. In this case, whilst the patient 
also received treatment with metformin for diabetes and atorvastatin for hyperlipidemia, 
there was no sign of coronary artery disease, serum potassium was normal, nor were there 
other obvious risk factors additional to solifenacin therapy and old age.  
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The majority of drugs that prolong the QT interval inhibit the human Ether-à-go-go Related 
Gene (hERG)-encoded potassium channel which mediates the rapid delayed rectifier current 
(IKr), and is integral to cardiac ventricular repolarisation (Hancox et al., 2008). Impaired 
repolarisation predisposes to development of early afterdepolarisations (EADs) and 
progression to drug-induced TdP. We were unable to find published evidence of hERG 
channel block by solifenacin; however, the drug has been reported to exhibit prolongation 
of the duration of Ca2+ transients and induce EAD-like signals in human induced pluripotent 
stem cell-derived cardiomyocytes (Zeng et al., 2016). This is suggestive of the capacity for a 
direct proarrhythmic effect. 
 
Common features of the three case reports that we identified are age >80 years and 
responsiveness to pacing. There also appeared to be a lack of sensitivity of the arrhythmia 
to magnesium sulphate. Two of the three patients had normal serum potassium; borderline 
hypokalemia, bradycardia and hypoglycaemia were present in one case. In all three cases, 
QTc intervals normalized on withdrawal of solifenacin. Rechallenge with solifenacin was not 
attempted in any case.  A QT interval nomogram has been proposed that allows estimation 
of the risk of developing TdP from QT interval – heart rate pairs; in this, values placed above 
the nomogram line are considered to be “at risk” (Chan et al., 2007; Waring et al., 2010).  
The measured QT intervals in solifenacin the first two case reports (600 ms and 680 ms) lie 
far above the nomogram line across the entire heart rate range, whilst values estimated 
from the QTc interval of the third case (QT interval of 500 ms and 516 ms respectively for 
Bazett’s and Fridericia’s corrections) also lie above the nomogram line. Thus, QT nomogram 
predicted risk for these three cases would have been consistent with the documented 
arrhythmias in each case.  We additionally interrogated publically available information 
from the European Medicines Agency (EMA) EudraVigilance database. Up to November 
2016, 15 individual cases of TdP had been reported, 11 of which had recovered/resolved, 3 
of which were resolving and for 1 of which the outcome was unknown. 13 of the 15 cases 
were between 65 and 85 years of age and 10 of 15 were female (European Medicines 
Agency, 2016).  Heart rate and QT interval information for these cases were not obtained. 
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The fact that most TdP cases were amongst elderly patients is notable, though perhaps not 
surprising given the primary indications for solifenacin use.  An increased risk of TdP in older 
patients may be linked to falls in serum testosterone and progesterone levels in men and 
women respectively (Tisdale, 2016). Cardiac ageing is also associated with ventricular 
fibrosis, which can facilitate development of re-entrant circuits (Biernacka and 
Frangogiannis, 2011). The contribution of such underlying factors to TdP development in the 
particular cases discussed here is not known. Considering all of the available information 
together, it seems prudent that elderly patients, especially those of >80 years, should be 
carefully evaluated before prescribing solifenacin and that the drug be avoided in patients 
with other known risk factors for TdP. Elderly females may be at particular risk.  
Disclosures:    None 
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